ResMed Inc. ($RMD) Stock Forecast: Down 5.1% Today

What is ResMed Inc.?

ResMed Inc. ($RMD) is a global leader in digital health, providing cloud-connected medical devices for the treatment of sleep apnea, COPD, and other chronic respiratory conditions. The company has recently reported strong quarterly results, exceeding analyst expectations and declaring a quarterly dividend.

Why is ResMed Inc. going down?

RMD stock is down 5.1% on May 29, 2026 17:41

• The strong bearish movement in ResMed Inc. ($RMD) today could be attributed to profit-taking and market sentiment reacting to insider selling activities.
• Despite the positive quarterly earnings report and increased stake by institutional investors, the significant reduction in shares by a specific entity and insider selling may have raised concerns among investors.
• The filing indicating the resale of shares by a brokerage services company and insider sales by an individual might have added selling pressure on the stock.
• Overall, the bearish movement in $RMD today seems to be a result of a combination of profit-taking, insider selling activities, and market sentiment reacting to these developments despite the strong quarterly performance.

RMD Price Chart

RMD Technical Analysis

RMD News

Fideuram Asset Management Ireland dac Acquires New Stake in ResMed Inc. $RMD

Fideuram Asset Management Ireland dac has acquired a new stake in ResMed Inc. (NYSE:RMD) during the fourth quarter, purchasing 18,991 shares valued at approximately $4.7 million. This comes as ResMed reported strong quarterly results, exceeding analyst expectations with EPS of $2.86 and revenue of $1.43 billion. The company also announced a quarterly dividend and holds a "Moderate Buy" consensus rating from analysts.

https://www.marketbeat.com/instant-alerts/filing-fideuram-asset-management-ireland-dac-acquires-new-stake-in-resmed-inc-rmd-2026-05-29/

Employees Retirement System of Texas Boosts Stock Holdings in ResMed Inc. $RMD

The Employees Retirement System of Texas significantly increased its stake in ResMed Inc. (NYSE:RMD) during the fourth quarter, purchasing an additional 6,480 shares to bring its total holdings to 28,780 shares valued at $6.93 million. This comes after ResMed reported strong quarterly results with earnings of $2.86 per share and revenue up 10.8% year over year, exceeding analyst expectations. The company also declared a quarterly dividend of $0.60 per share, and analysts rate the stock a "Moderate Buy" with a consensus price target of $286.18.

https://www.marketbeat.com/instant-alerts/filing-employees-retirement-system-of-texas-boosts-stock-holdings-in-resmed-inc-rmd-2026-05-28/

Fisher Asset Management LLC Raises Stake in ResMed Inc. $RMD

Fisher Asset Management LLC increased its stake in ResMed Inc. by 10.2% during the fourth quarter, bringing its total holdings to 66,972 shares valued at approximately $16.1 million. This increase follows ResMed's strong quarterly earnings report, where the company exceeded analyst estimates with revenues of $1.43 billion. Analysts currently rate ResMed as a "Moderate Buy" with an average price target of $286.18, and the company also announced a quarterly dividend of $0.60 per share.

https://www.marketbeat.com/instant-alerts/filing-fisher-asset-management-llc-raises-stake-in-resmed-inc-rmd-2026-05-28/

AlphaQuest LLC Sells 8,469 Shares of ResMed Inc. $RMD

AlphaQuest LLC significantly reduced its stake in ResMed Inc. by selling 8,469 shares, decreasing its position by 55.1% to 6,894 shares valued at $1.66 million. This move aligns with recent insider selling from ResMed's CEO and a Director. Despite these sales, the company reported strong quarterly earnings, beating expectations, and analysts currently rate the stock a "Moderate Buy" with a consensus target price of $286.18.

https://www.marketbeat.com/instant-alerts/filing-alphaquest-llc-sells-8469-shares-of-resmed-inc-rmd-2026-05-28/

Form 144: RMD (NYSE) affiliate lists 8,000 shares; insider sold 2,000

A Form 144 filing for ResMed Inc. (RMD) reports that 8,000 shares associated with Fidelity Brokerage Services LLC are listed for resale, with an aggregate value of $1,672,560.00. The filing also discloses two past sales by insider Brett Sandercock: 1,000 shares for $254,300.00 on March 2, 2026, and another 1,000 shares for $224,310.00 on April 1, 2026. These shares originated from Restricted Stock Vesting on November 21, 2019.

https://www.stocktitan.net/sec-filings/RMD/144-resmed-inc-sec-filing-b160ded7330c.html

Trending Today

Oracle Corporation ($ORCL) Stock Forecast: Up 9.1% Today

Intuit Inc. ($INTU) Stock Forecast: Up 5.0% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 10.0% Today

Clover Health Investments Crop. ($CLOV) Stock Forecast: Down 5.6% Today

American Eagle Outfitters Inc. ($AEO) Stock Forecast: Down 15.0% Today

NetApp Inc. ($NTAP) Stock Forecast: Up 27.5% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.2% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Down 5.1% Today

Unity Software ($U) Stock Forecast: Up 5.5% Today

Adobe Inc. ($ADBE) Stock Forecast: Up 5.6% Today

ResMed Inc. Price History

30.00.2026 - RMD Stock was down 0.8%

• The strong bearish movement in ResMed's stock today could be attributed to profit-taking by investors after a period of positive performance and price appreciation.
• Despite the impressive Q2 results and increased institutional interest in the company's stock, the notable insider selling by CEO Michael J. Farrell and others might have raised concerns among investors about the future outlook of the company.
• Additionally, the market may be reacting to the Hold rating reiterated by an independent analyst, indicating a more cautious stance on the stock despite the positive financial performance.
• Overall, the bearish movement could be a result of a combination of factors, including profit-taking, insider selling, and cautious analyst sentiment, leading to a temporary dip in the stock price.

13.00.2026 - RMD Stock was down 0.3%

• Bogart Wealth LLC notably increased its stake in ResMed Inc., while company insiders have been selling shares possibly suggesting differing views on the company's potential.
• ResMed's robust Q3 earnings report and revenue growth might have initially boosted investor confidence, but recent insider selling by the CEO and a director could have raised concerns.
• The sale of shares by ResMed director Peter C. Farrell under a pre-arranged trading plan, amid varied analyst ratings, could have intensified the negative sentiment surrounding the stock.
• Despite the positive earnings and institutional investments, the mixture of analyst ratings, insider selling, and market apprehensions about the company's future likely contributed to the bearish movement in ResMed's stock price today.

05.00.2026 - RMD Stock was up 1.3%

• The significant insider selling and institutional ownership of ResMed Inc. could have initially raised concerns among investors, but the company's ability to surpass EPS and revenue expectations likely reassured the market.
• ResMed's strategic shift towards a connected ecosystem for sleep and respiratory care may have sparked investor optimism about the company's long-term growth potential and competitive edge.
• The high institutional ownership, particularly with influential shareholders like The Vanguard Group, Inc., suggests a level of confidence in ResMed's future performance, potentially contributing to the bullish movement in the stock.
• Overall, the combination of positive financial results, strategic positioning in the market, and strong institutional support likely drove the bullish momentum in ResMed's stock today.

01.04.2026 - RMD Stock was down 5.0%

• Several financial institutions adjusted their price targets for ResMed, with mixed reactions – one decreased while another increased the target. This variance in analyst sentiment could have impacted the bearish movement.
• Despite strong Q3 results and positive corporate developments including the acquisition of Noctrix and advancements in CPAP therapies, the market response may have been influenced by the overall analyst sentiment.
• The announcement of a quarterly dividend increase and ResMed's consistent financial performance were viewed positively. However, the stock's decline could be attributed to broader market conditions or investors taking profits.
• Additionally, external factors such as a recent cyberattack on a competitor could have contributed to the bearish movement of ResMed's stock.

01.04.2026 - RMD Stock was down 5.7%

• Today, there was a significant downward movement in ResMed's stock, potentially due to the Q3 2026 results showing mixed performance: surpassing expectations in EPS growth but falling short in revenue.
• The market reacted negatively to the revenue miss despite the company exceeding earnings forecasts and reporting increased revenue, leading to a bearish trend in the stock.
• Factors such as the acquisition of Noctrix for $340 million, the CFO's retirement announcement, and the focus on GLP-1 therapies may have created uncertainty among investors, contributing to the decline in the stock price.
• The stable stock performance in aftermarket trading following the mixed results could be causing concern about the company's future growth prospects and competitiveness in the market.

04.01.2026 - RMD Stock was up 2.6%

• Institutional investors acquiring significant stakes in ResMed Inc. indicate growing confidence in the company's future prospects, contributing to the bullish movement.
• Despite insider selling trends, the positive quarterly results and dividend announcement have likely boosted investor sentiment towards ResMed.
• Emphasizing ResMed as a stable long-term investment in the healthcare sector reinforces the positive market movement, attracting more investors to the stock.
• The overall bullish sentiment towards ResMed is further supported by the insider sell alert, which, despite the selling activity, did not deter investors, possibly due to the company's strong fundamentals and growth potential.

29.04.2026 - RMD Stock was down 5.1%

• The strong bearish movement in ResMed Inc. ($RMD) today could be attributed to profit-taking and market sentiment reacting to insider selling activities.
• Despite the positive quarterly earnings report and increased stake by institutional investors, the significant reduction in shares by a specific entity and insider selling may have raised concerns among investors.
• The filing indicating the resale of shares by a brokerage services company and insider sales by an individual might have added selling pressure on the stock.
• Overall, the bearish movement in $RMD today seems to be a result of a combination of profit-taking, insider selling activities, and market sentiment reacting to these developments despite the strong quarterly performance.

25.02.2026 - RMD Stock was down 3.2%

• A downgrade from Buy to Hold may have influenced investor sentiment, leading to a sell-off of ResMed's shares.
• Despite maintaining a Buy rating and a positive outlook, the market might have reacted more strongly to the rating change.
• An increased stake by Nordea Investment Management indicates long-term confidence in ResMed but short-term market dynamics could have overshadowed this positive development.
• The FDA approval of LivaNova's aura6000 System for OSA treatment may have created some competition concerns among investors, impacting ResMed's stock performance negatively.

11.01.2026 - RMD Stock was down 6.1%

• Significant selling activity by Baader Bank Aktiengesellschaft and CEO Michael Farrell, reducing their stakes in ResMed, might have signaled a lack of confidence in the company's future performance, contributing to the bearish trend.
• Despite ResMed's strong quarterly results and analyst recommendations, insider selling totaling over $4.6 million could have raised concerns among investors about the company's growth potential.
• The high institutional ownership of 73% in ResMed indicates that any changes in their positions could heavily influence the stock price, potentially leading to a bearish sentiment as seen today.
• A comparison with Ross Stores in discussions about market interest highlights the contrasting performance and market perception between the two companies, potentially leading investors to shift their focus away from ResMed, contributing to the bearish movement.

12.01.2026 - RMD Stock was down 5.1%

• The stock's decline could be linked to CEO Michael Farrell selling a significant number of shares, leading to investor concerns regarding the company's future.
• The reduction in ResMed's stake by Baader Bank Aktiengesellschaft may have also fueled negative sentiment, despite the company surpassing quarterly expectations.
• Market reaction to the ongoing clinical trial of ResMed's new software tool for sleep apnea patients might be influencing investor decisions, awaiting substantial results.
• Insider selling, institutional adjustments, and trial progress are potential factors contributing to today's bearish movement in ResMed's stock.